LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives $94.40 Average PT from Brokerages

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been assigned an average rating of “Buy” from the seven ratings firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $94.40.

A number of research analysts recently commented on LMAT shares. JMP Securities raised their price target on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 20th. Roth Mkm restated a “buy” rating and issued a $100.00 price target on shares of LeMaitre Vascular in a research report on Friday, May 31st. Lake Street Capital started coverage on LeMaitre Vascular in a research report on Friday, August 2nd. They issued a “buy” rating and a $105.00 price target on the stock. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Tuesday, August 27th. Finally, Roth Capital upgraded LeMaitre Vascular to a “strong-buy” rating in a research report on Friday, May 31st.

LeMaitre Vascular Price Performance

Shares of LMAT stock opened at $90.00 on Friday. The stock has a market cap of $2.02 billion, a PE ratio of 59.60, a price-to-earnings-growth ratio of 2.28 and a beta of 0.88. The stock has a 50-day moving average of $86.44 and a 200-day moving average of $77.52. LeMaitre Vascular has a one year low of $44.27 and a one year high of $92.90.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. LeMaitre Vascular had a return on equity of 12.41% and a net margin of 18.33%. The business had revenue of $55.85 million during the quarter, compared to analysts’ expectations of $54.98 million. During the same period in the prior year, the business earned $0.37 EPS. LeMaitre Vascular’s revenue for the quarter was up 11.4% compared to the same quarter last year. As a group, research analysts anticipate that LeMaitre Vascular will post 1.85 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, August 29th. Investors of record on Thursday, August 15th were issued a dividend of $0.16 per share. The ex-dividend date of this dividend was Thursday, August 15th. This represents a $0.64 annualized dividend and a yield of 0.71%. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 42.38%.

Insider Buying and Selling

In other LeMaitre Vascular news, Director David B. Roberts sold 3,063 shares of the business’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total value of $251,380.41. Following the transaction, the director now owns 14,114 shares of the company’s stock, valued at $1,158,335.98. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, Director David B. Roberts sold 3,063 shares of the company’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total transaction of $251,380.41. Following the transaction, the director now owns 14,114 shares of the company’s stock, valued at approximately $1,158,335.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO George W. Lemaitre sold 12,976 shares of the company’s stock in a transaction on Friday, July 12th. The shares were sold at an average price of $86.07, for a total value of $1,116,844.32. Following the transaction, the chief executive officer now directly owns 1,985,358 shares in the company, valued at approximately $170,879,763.06. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 43,251 shares of company stock worth $3,714,994. 10.79% of the stock is owned by corporate insiders.

Institutional Trading of LeMaitre Vascular

A number of institutional investors have recently added to or reduced their stakes in the stock. Shaker Investments LLC OH increased its stake in LeMaitre Vascular by 1.3% in the 1st quarter. Shaker Investments LLC OH now owns 13,658 shares of the medical instruments supplier’s stock worth $906,000 after acquiring an additional 169 shares during the last quarter. GAMMA Investing LLC increased its position in shares of LeMaitre Vascular by 57.0% during the 2nd quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock valued at $45,000 after purchasing an additional 199 shares during the last quarter. nVerses Capital LLC increased its position in shares of LeMaitre Vascular by 33.3% during the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock valued at $66,000 after purchasing an additional 200 shares during the last quarter. Albion Financial Group UT increased its position in shares of LeMaitre Vascular by 5.6% during the 1st quarter. Albion Financial Group UT now owns 3,974 shares of the medical instruments supplier’s stock valued at $264,000 after purchasing an additional 212 shares during the last quarter. Finally, Texas Permanent School Fund Corp increased its position in shares of LeMaitre Vascular by 1.3% during the 1st quarter. Texas Permanent School Fund Corp now owns 17,341 shares of the medical instruments supplier’s stock valued at $1,151,000 after purchasing an additional 225 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.